Document:

EX-10.14

Exhibit 10.14

SUBSCRIPTION AGREEMENT

     SUBSCRIPTION AGREEMENT, dated as of May 15, 2007 (this “Agreement”) by and
among Healthcare Services, Inc., a Delaware corporation (the “Company”) and
Ascension Health, a Missouri not-for-profit corporation (“Ascension” or
“Purchaser”).

W I T N E S S E T H

     WHEREAS, Purchaser currently owns shares of the Company’s Series B Common Stock
subject to that certain Restricted Stock Agreement dated as of November 7, 2004 between
Ascension Health and the Company (the “Restricted Stock Agreement”); and

     WHEREAS, Purchaser, wishes to purchase, and the Company wishes to sell to Purchaser,
669,284 additional shares of the Company’s Series B Common Stock, par value $0.01 per
share (the “Additional Series B Stock” or the “Purchased Shares”) on the
terms and subject to the conditions set forth in this Agreement and those of the
Restricted Stock Agreement.

     NOW THEREFORE, in consideration of the mutual covenants of the parties as hereinafter
set forth and other good and valuable consideration, the receipt and sufficiency of which
hereby are acknowledged, the parties hereto, intending to be legally bound hereby, agree
as follows:

ARTICLE I.

THE PURCHASED SHARES

Section 1.01. Issuance, Sale and Delivery of Shares. Subject to the terms and
conditions of this Agreement, and the Restricted Stock Agreement, at the Closing (as
defined in Section 1.02), the Company agrees to issue and sell to each Purchaser, and
Purchaser hereby agrees to purchase from the Company, 669,284 shares, at the aggregate
purchase price of $5,488,128 (“Purchase Price for Purchased Shares”).

Section 1.02. Closing. The closing shall take place at the offices of Katten
Muchin Rosenman LLP, 525 W. Monroe Street, Chicago, Illinois 60661-3693, at 10:00 a.m.,
Central time, on June 7, 2007, or at such other location, date and time as may be agreed
upon between the Purchaser and the Company (such closing being called the
“Closing” and such date and time being called the “Closing Date”). At the
Closing, the Company shall issue and deliver to Purchaser a stock certificate in
definitive form, registered in the name of Purchaser, representing the Purchased Shares
being purchased by it at the Closing. As payment in full for the Purchased Shares being
purchased by it under this Agreement, and against delivery of the stock certificates
therefor as aforesaid, on the Closing Date Purchaser shall transfer the amount of
$5,488,128, to the account of the Company by wire transfer of immediately available funds.

 

 

ARTICLE II.

COMPANY REPRESENTATIONS AND WARRANTIES

The Company hereby represents and warrants to the Subscriber as of the date hereof that:

Section 2.01. Organization and Good Standing. The Company is a corporation duly organized,
validly existing and in good standing under the laws of the State of Delaware and has all requisite
corporate power and authority to own its properties and assets and to carry on its business as now
conducted and as presently proposed to be conducted.

Section 2.02. Validity of Securities. The Securities, when issued in accordance with the
terms of this Agreement, will be duly authorized, validly issued, fully paid and nonassessable.

Section 2.03. Capitalization. The outstanding capital of the Company, on a fully diluted basis,
as of 12-31-06 is set forth on Exhibit A hereto and there have been no changes to the outstanding
capital since that time, other than the transaction contemplated by this Subscription Agreement.

Section 2.04. Due Authorization. All action on the part of the Company necessary for the
authorization, execution and delivery of, and the performance of all obligations of the Company
under, this Agreement has been taken.

Section 2.05. Valid Issuance of Purchased Shares. The Purchased Shares which are being
purchased by Purchaser hereunder, when issued, sold and delivered in accordance with the terms
hereof for the consideration expressed herein, will be duly and validly issued, fully paid and
nonassessable and, based in part upon the representations of Purchaser in this Agreement, will be
issued in compliance with all applicable federal and state securities laws.

Section 2.06. Governmental Consents. Assuming the accuracy of the representations made by
the Purchaser in Article III of this Agreement, no consent, approval, order or authorization of, or
registration, qualification, designation, declaration or filing with, any federal, state, local or
provincial governmental authority on the part of the Company is required in connection with the
consummation of the transactions contemplated by this Agreement, except such filings as have been
made prior to the Closing, or such post-closing filings as may be required under Rule 506 of
Regulation D of the Securities Act of 1933, as amended, and applicable state securities laws, which
will be timely filed within the applicable periods therefore

Section 2.07. Litigation. There is no action, suit, proceeding or investigation pending
or currently threatened in writing against the Company which questions the validity of this
Agreement or the right of the Company to enter into it, or to consummate the transactions
contemplated hereby, or which might result, either individually or in the aggregate, in any
material adverse changes in the assets, condition, affairs or prospects of the Company, financially
or otherwise, or any change in the current equity ownership of the Company, nor is the Company
aware that there is any basis for the foregoing. The Company is not a

2

 

party or subject to the provisions of any order, writ, injunction, judgment or decree of any court
or government agency or instrumentality.

Section 2.08. Compliance with Other Instruments. The Company is not in violation or
default of any provisions of its Restated Articles or Amended and Restated Bylaws or in any
material respect of any provision of any mortgage, indenture, agreement, instrument, or contract to
which it is a party or by which it is bound, or to its knowledge, of any federal or state judgment,
order, writ, decree, statute, rule, or regulation applicable to the Company. The execution,
delivery and performance of this Agreement and the consummation of the transactions contemplated
hereby will not result in any such violation or be in material conflict with or constitute, with or
without the passage of time and giving of notice, either a material default under any such
provision, instrument, judgment, order, writ, decree or contract or an event which results in the
creation of any material lien, charge or encumbrance upon any assets of the Company.

Section 2.09. Title to Property and Assets. The Company owns its property and assets free
and clear of all mortgages, liens, loans and encumbrances, except such encumbrances and liens which
arise in the ordinary course of business and do not materially impair the Company’s ownership or
use of such property or assets. With respect to the property and assets it leases, the Company is
in compliance with such leases and, to its knowledge, holds a valid leasehold interest free of any
liens, claims or encumbrances.

Section 2.10. Insurance. The Company has in full force and effect valid policies of
workers’ compensation insurance and of insurance with respect to their properties and business of
the kinds and amounts not less than is customarily obtained by corporations of similar size engaged
in the same or similar businesses and similarly situated, including, without limitation, insurance
against loss, damage, fire, theft, public liability and other risks.

Section 2.11. Obligations to Related Parties. Except as provided in the Schedule of
Exceptions, there are no obligations of the Company to officers, directors, stockholders, or
employees of the Company or its affiliates other than (i) for payment of salary for services
rendered, (ii) reimbursement for reasonable expenses incurred on behalf of the Company and (iii)
for other standard employee benefits made generally available to all employees (including stock
option agreements outstanding under any stock option plan approved by the Board of Directors of the
Company).

Section 2.12. No Conflict. The Company has the legal right, capacity and authority to enter
into this Agreement and the execution, delivery and performance of this Agreement by the Company
have been duly authorized by all necessary corporate action. The execution, delivery and performance
of this Agreement by the Company will not violate, conflict with, or cause a default under its
certificate of incorporation and by-laws, or any agreement, lease, mortgage, instrument or other
contract to which the Company is a party or by which it is bound.

3

 

ARTICLE III.

REPRESENTATIONS AND WARRANTIES OF THE PURCHASER

Purchaser represents and warrants to the Company that:

Section 3.01. Information Received. The Purchaser:

          (a) has received such documents, materials and information as the Purchaser deems necessary
or appropriate for evaluating an investment in the Company;

          (b) has carefully read and understands these materials; and

          (c) has made such further investigation as was deemed appropriate to obtain additional
information to verify the accuracy of such materials and to evaluate the merits and risks of its
investment in the Purchased Shares.

Section 3.02. Due Diligence. The Purchaser has had an opportunity to ask questions of and
receive answers from the officers of the Company, concerning the terms and conditions of this
investment, and all such questions have been answered to the full satisfaction of the undersigned.

Section 3.03. No Solicitation. The Purchaser confirms that the Purchased Shares were not
offered to the Purchaser by any means of general solicitation or general advertising.

Section 3.04. Investor Status. The Purchaser:

          (a) has such knowledge and experience in financial and business matters as to be capable of
evaluating the merits and risks of an investment in the Company;

          (b) is able to bear the economic risks of an investment in the Purchased Shares, and at the
present time could afford a complete loss of such investment; and

          (c) is acquiring the Purchased Shares for the Purchaser’s own account, for investment
purposes only, and not with a view towards the sale or other distribution thereof, in whole or in
part.

Section 3.05. No Registration. The Purchaser understands that the Purchased Shares have not
been registered under the securities laws of any state, under the Securities Act of 1933, as
amended (the “Act”) or under the securities laws of any other country and are offered in
reliance on exemptions therefrom (which depend upon, among other things, the bona fide nature of
the investment intent and the truth and accuracy of such Purchaser’s representations as expressed
herein), that the Purchased Shares have not been approved or disapproved by the Securities and
Exchange Commission, by any other federal or state agency or by any other equivalent foreign
agency.

4

 

Section 3.06. Nature of Investment. The Purchaser recognizes that the Company is a highly
speculative venture involving a high degree of financial risk and the Purchaser is familiar with
the nature of, and risks attendant to, investments in securities of the type being subscribed for
and has determined that the purchase of such securities is consistent with the Purchaser’s
investment objectives.

Section 3.07. Transferability. The Purchaser understands that: (a) the Purchased shares
are subject to the terms of the Restricted Stock Agreement which includes restrictions on the
transferability of the Purchased Shares; (b) except as set forth in, by and among the Company and
the Purchasers, the Purchaser has no rights to require the Purchased Shares to be registered
under the Act or any equivalent foreign agency; (c) there will be no public market for the
Purchased Shares; and (d) it may not be possible for the Purchaser to liquidate the Purchaser’s
investment in the Company and accordingly, the Purchaser may have to hold the Purchased Shares,
and bear the economic risk of this investment, indefinitely.

Section 3.08. Power and Authority; Due Authorization. If the Purchaser is a partnership,
corporation, limited liability company, trust, or other entity, the person executing this
Agreement has the full power and authority to execute and deliver this Agreement on behalf of the
subscribing entity for whom he or she is executing this Agreement, such entity has the full power
and authority to execute and deliver this Agreement, all action on the part of the such entity
necessary for the authorization, execution and delivery of, and the performance of all obligations
of such entity under, this Agreement has been taken and such entity was not formed solely for the
purpose of investing in Purchased Shares.

Section 3.09. Separate Representation. The Purchaser acknowledges that it has been advised
to consult with its own attorney regarding legal matters concerning the Company and to consult
with its tax advisor regarding the tax consequences of participating in the Company.

Section 3.10. Company Representations. Except as set forth herein, the Purchaser is not
relying on any representations, warranties, projections, covenants or other statements or
commitments, written or oral, by the Company, its officers, directors, representatives or agents
in connection with its investment in the Purchased Shares.

Section 3.11. Accredited Investor. The Purchaser is either

          (a) a natural person and he or she (i) has an individual net worth, or joint net worth with
his or her spouse, in excess of US$1,000,000 or (ii) had an individual income in excess of
US$200,000 in each of the two most recent years or joint income with his or her spouse in excess
of US$300,000 in each of those years and has a reasonable expectation of reaching the same income
level in the current year; or

          (b) not a natural person and (i) all of its equity owners are natural persons as to each of
whom the representation and warranty set forth in Section 3.12 hereof would be true and correct
or (ii) it is a corporation, business trust, or partnership,

5

 

limited liability company, or irrevocable trust not formed for the specific purpose of acquiring
the Purchased Shares, with total assets in excess of US$5,000,000.

ARTICLE IV.

MISCELLANEOUS

Section 4.01. Survival of Representations and Warranties. All representations and
warranties contained in this Agreement shall survive the execution and delivery of this
Agreement.

Section 4.02. Consent to Amendments; Waivers. This Agreement may be amended or modified
upon the written agreement of the parties hereto. Any waiver, permit, consent or approval of any
kind or character on the part of any party of any provisions or conditions of this Agreement must
be made in writing and shall be effective against the party executing such waiver, permit,
consent or approval only to the extent specifically set forth in such writing. No other course of
dealing between the parties or any delay in exercising any rights hereunder shall operate as a
waiver of any rights of any such parties.

Section 4.03. Notices. All notices, requests, consents and other communications hereunder
shall be in writing and shall be delivered in person, mailed by certified or registered mail,
return receipt requested, or sent by telecopier or telex, addressed as follows:

          (a) if to the Company, at 401 North Michigan Avenue, Suite 2700, Chicago, Illinois 60611,
Attn: Mary Tolan, Chief Executive Officer, with a copy to Greg Kazarian, Senior Vice President and
General Counsel; and

          (b) if to Purchaser, at 4600 Edmundson Road, St. Louis, Missouri 63134, Attn: Anthony
Speranzo, Senior Vice President and Chief Financial Officer, with a copy to Joseph R. Impicciche,
Senior Vice President and General Counsel

     or, in any such case, at such other address or addresses as shall have been furnished in
writing by such party to the others.

Section 4.04. Back Up Withholding. The undersigned represents, warrants and certifies
that he is not subject to “back up withholding” pursuant to Section 3406 of the Internal Revenue
Code of 1986, as amended, and that he has provided his correct tax identification number below.

Section 4.05. Binding Effect. This Agreement and the representations and warranties
contained herein shall be binding upon the heirs, executors, administrators, and other successors
of the undersigned and this Agreement shall inure to the benefit of and be enforceable by the
Company. If there is more than one signatory hereto, the obligations, representations,
warranties, and agreements of the undersigned are made jointly and severally.

6

 

Section 4.06. Governing Law; Choice of Forum. This Agreement shall be governed by and
construed and enforced in accordance with the laws of the State of Delaware, without regard to
principles of conflicts of law. Any and all litigation arising out of this Agreement shall be
conducted only in courts located in the State of Illinois.

Section 4.07. No Third Party Beneficiaries. This Agreement is intended and agreed to be
solely for the benefit of the parties hereto and the members of the Company, and no other person
or entity shall accrue any benefit, claim or right of any kind whatsoever pursuant to, under, by
or through this Subscription Agreement.

Section 4.08. Entire Agreement. This Agreement, including the Schedules and Exhibits
hereto, constitutes the sole and entire agreement of the parties with respect to the subject
matter hereof. All Schedules and Exhibits hereto are hereby incorporated herein by reference.

Section 4.09. Construction. Common nouns and pronouns used in this Subscription Agreement
shall be deemed to refer to the masculine, feminine, neuter, singular and plural, as the identity
of the person may in the context require. This Agreement shall not be construed against any party
for having drafted it.

Section 4.10. Counterparts/Reproduction of Documents. This Agreement may be executed in
any number of counterparts, each of which shall be deemed an original, but all such counterparts
shall together constitute one and the same instrument. This Agreement may be executed and
delivered by facsimile signature, which signature shall be deemed to be an original. Upon
execution in accordance herewith, this Agreement may be reproduced by any photographic,
photostatic, microfilm, optical disk, micro-card, miniature photographic or other similar process,
each of which reproduction of this Agreement shall be deemed to be an original.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK

SIGNATURES FOLLOW ON NEXT PAGE.]

7

 

     IN WITNESS WHEREOF, the undersigned entities have caused this Agreement to be executed by
their duly authorized officers as of the date first set forth above.

	 	 	 	 	 
	 	COMPANY:

HEALTHCARE SERVICES, INC.

 	 
	 	By:  	/s/ Mary Tolan
 	 
	 	Name:  	Mary Tolan 	 
	 	Title:  	Chief Executive Officer 	 
	 
	 	ASCENSION HEALTH:

 	 
	 	By:  	/s/ Anthony Speranzo
 	 
	 	Name:  	Anthony Speranzo 	 
	 	Title:  	Senior Vice President and
 Chief Financial Officer 	 
	 

 

 

ACCRETIVE HEALTH

FULLY DILUTED SHARES

As of: December 31, 2006

	 	 	 	 	 
	Accretive Health Fully Diluted Shares
	 	 	 	 
	 
	 	 	 	 
	Series A Preferred as if Converted
	 	 	9,905,674	 
	Series D Preferred
	 	 	1,267,224	 
	Series B Outstanding
	 	 	3,902,374	 
	Series B Warrants
	 	 	213,100	 
	Series C Outstanding
	 	 	3,733,051	 
	Series C Options
	 	 	2,454,862	 
	Series C Warrants
	 	 	833,334	 
	 
	 	 	 	 
	Total Shares as of December 31, 2006
	 	 	22,309,619	 
	 
	 	 	 	 
	 
	 	 	 	 
	Ascension Anti-Dilution Warrants
	 	 	 	 
	Series B Outstanding
	 	 	902,374	 
	Series B Warrants
	 	 	213,100	 
	 
	 	 	 	 
	Total Ascension
	 	 	1,115,474	 
	 
	 	 	 	 
	 
	 	 	 	 
	Ascension as a % of Total Shares
	 	 	5.00	%
	 
	 	 	 	 
	Ascension Anti-Dilution Warrants - Detail
	 	 	 	 
	Dec. 2004 true-up to 5%
	 	 	19,189	 
	Shultz
	 	 	9,447	 
	2005 Series A Capital Funding - Series 14/MT
	 	 	22,787	 
	Zimmerman Warrants
	 	 	43,860	 
	Dec 2005 Capital Raise - Series D as if converted
	 	 	66,696	 
	Dec 2005 Series C - Option Pool
	 	 	35,368	 
	Sure Decisions Closing Shares
	 	 	5,251	 
	Sure Decisions Option Pool
	 	 	10,502	 
	 
	 	 	 	 
	Total Anti-Dilution Warrants thru 12/31/06
	 	 	213,100EX-10.15

Exhibit 10.15

February 17, 2004

Mr. Michael Zimmerman

Zimmerman and Associates

The following term sheet is intended to memorialize the agreements reached between you and Health
Care Services, Inc. d/b/a Accretive Health. The parties anticipate executing more definitive
agreements regarding this subject matter, however it is their intention to be bound by this term
sheet upon its execution.

Zimmerman Equity

In exchange for the license rights, exclusivity and information sharing provided for below,
Accretive Health will grant Mike Zimmerman stock warrants granting him a 2.5% at the price
determined by the Accretive Health Board to be fair market value (FMV) at the time the warrants are
granted.

Additionally, Zimmerman Associates will have the right to earn the right additional Stock Warrants
as compensation for its support and participation of Accretive Health’s Sales Efforts. These
additional Stock Warrants will be earned when Accretive Health signs a Managed Services Agreement
with a hospital/system were Zimmerman has been Accretive Health’s “sponsor” with respect to that
institution. Zimmerman will be considered Accretive’s “sponsor” to an institution where
Zimmerman’s efforts resulted in Accretive Health securing a meeting with a C-level executive or
Board member, or where Accretive Health and Zimmerman agreed that Zimmerman is entitled to
“sponsor” status based on other efforts. The additional Stock Warrants will be earned as follows:

	 	1.	 	2.5% for Ascension, or a system of similar size and prestige, provided that the
scope of the MSA includes a majority of system volumes; or
	 
	 	2.	 	1.25% for each system other than those which fit the description above.
	 
	 	3.	 	These Additional Stock Warrants will be available for up to 2.5% of the equity
in Accretive Health based on its February 2004 capitalization structure fully diluted
for its first $10 million in financing.
	 
	 	4.	 	These Additional Stock Warrants will be available for MSAs with institutions
where the introduction by Zimmerman has occurred before 12/31/05 and which have been
signed by 12/31/06.
	 
	 	5.	 	These Additional Stock Warrants will be exercisable at the price determined by
the Accretive Health Board to be fair market value (FMV) at the time the warrants are
earned.

Giving effect to the 2.5% interest available for the license and exclusivity rights and the 2.5%
interest available as a “sponsor” Zimmerman will have the opportunity to secure a 5% interest in
Accretive Health.

 

 

Information Sharing/Non-competition

In consideration for the stock warrants granted to Mike Zimmerman above, Zimmerman will grant
Accretive Health exclusive access to its revenue cycle methodologies, tools, technology,
benchmarking information and other intellectual property, including any information developed by it
during the period of any agreement between it and Accretive Health. This will be accomplished
through an exclusive license for use of this information and intellectual property in the managed
services environment. Managed services will include BPO, outsourcing and similar opportunities.

Further, Zimmerman agrees that it will not enter into any other relationship with any Managed
Services Provider which competes directly or indirectly with Accretive Health during the period of
its agreement with Accretive Health and for a period of three years from the termination of the
agreement. During that same period, Zimmerman agrees that it will not refer or recommend any other
revenue cycle managed service or outsourcing firm other than Accretive Health.

Accretive Health and Zimmerman may work collectively in connection with various client projects in
the future. Accretive Health agrees that it will share those service and delivery methodologies
with Zimmerman in connection with those joint projects. Zimmerman agrees to keep this information
confidential, protect it in the manner which it protects its own confidential information and to
limit its use to its own consulting work on behalf of its clients.

Further, Accretive Health agrees that it will not enter into any other relationship with any
Revenue Cycle Consulting Firm which competes directly or indirectly with Zimmerman during the
period of its agreement with Accretive Health and for a period of three years from the termination
of the agreement. During that same period, Accretive Health agrees that it will not refer or
recommend any other revenue cycle consulting firm other than Zimmerman.

Sales Support

Zimmerman will assist Accretive Health in its sales efforts as required. Zimmerman will provide
advertising space in its publications at a nominal cost and will provide presentation opportunities
at its conferences. Zimmerman will use its best efforts to create presentation opportunities for
Accretive Health with its customers and at industry events and conferences. Mary Tolan and Mike
Zimmerman, in their discretion, may also form and convene a group of industry thought leaders to
serve as an Advisory Board to Accretive Health which they will Co-Chair.

	 	 	 	 	 
	Zimmerman Associates

/s/ Michael Zimmerman

	 	Accretive Health

/s/
Mary Tolan

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00163-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00163-of-00352.parquet"}]]